Relationship between excision repair cross-complementation group 1 methylation and sensitivity to cisplatin-based concurrent chemoradiotherapy in cervical squamous cell carcinoma
Bai Zhoulan,Ma Jianping,He Jianli,Zhang Yuhui,Hai Ping,Feng Yangyang,Wang Yangyang,Zhe Hong
Department of Radiation Oncology,Ningxia Medical University General Hospital Cancer Hospital,Yinchuan 750004,China
Abstract：Objective To investigate the correlation of the excision repair cross-complementation group 1(ERCC1) gene methylation status with sensitivity to cisplatin-based concurrent chemoradiotherapy and clinical pathological characteristics in patients with cervical squamous cell carcinoma (CSCC). Methods Methylation specific polymerase chain reaction was used to determine the ERCC1 gene methylation status in cervical tissue from 20 healthy people and 60 patients with CSCC. All patients with CSCC were treated with cisplatin-based concurrent chemoradiotherapy. The treatment outcomes were evaluated using the Response Evaluation Criteria in Solid Tumors. Based on the treatment outcomes, patients with a complete response were assigned to chemoradiotherapy-sensitive group, and patients with a partial response, stable disease, or progressive disease were assigned to chemoradiotherapy-resistant group. Comparison of the ERCC1 gene methylation status between the two groups was made by χ2 test, and multivariate logistic regression analysis was used to analyze the relationship of the ERCC1 gene methylation status with various clinical pathological characteristics and sensitivity to chemoradiotherapy. Results The ERCC1 gene methylation rate was significantly higher in cervical tissue with CSCC than in normal cervical tissue (60% vs. 0%, P=0.000). The multivariate analysis showed that ERCC1 gene methylation was an independent influencing factor for sensitivity to cisplatin-based concurrent chemoradiotherapy in CSCC (P=0.022);ERCC1 gene methylation was significantly correlated with histological grade of CSCC (P=0.030);there wasno significant relationship of ERCC1 gene methylation with clinical pathological characteristics including age tumor size, lymph node metastasis, FIGO stage, and pretreatment hemoglobin and platelet count (P=0.729,0.707,0.340,0.747,0.073,1.000). Conclusions The ERCC1 gene promoter methylation status may be involved in the development and progression of CSCC. It may also influence the sensitivity of patients with CSCC to cisplatin-based concurrent chemoradiotherapy by playing a role in cell differentiation.
Bai Zhoulan,Ma Jianping,He Jianli et al. Relationship between excision repair cross-complementation group 1 methylation and sensitivity to cisplatin-based concurrent chemoradiotherapy in cervical squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 525-528.
[1] Rose PG,Bundy BN,Watkins EB,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J].N Engl J Med,1999, 340(15):1144-1153. [2] Whitney CW,Sause W,Bundy BN,et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as anadjunct to radiation therapy in stage ⅡB-IVA carcinoma of the cervix with negative para-aortic lymph nodes:a Gynecologic Oncology Group and Southwest-Oncology Group study[J]. J Clin Oncol,1999,17(5):1339-1348. [3] Bai ZL,Wang YY, Zhe H,et al. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma[J].Radiat Oncol,2012,7:221.DOI:10.1186/1748－717X-7-221. [4] Lima LMC,de Souza LR,da Silva TF,et al. DNA repair gene excision repair cross complementing-group 1(ERCC1) in head and neck squamous cell carcinoma:analysis of methylation and polymorphism (G19007A),protein expression and association with epidemiological and clinicopathological factors[J].Histopathology,2012,60(3):489-496.DOI:10.1111/j.1365-2559.2011.04062.x. [5] Wang X,Zhao J,Yang L,et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer[J].Med Oncol,2010,27(2):484-490.DOI:10.1007/s12032-009-9239-3. [6] Jiang J,Liang X,Zhou X,et al. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer:a meta-analysis[J]. Mol Biol Rep,2012,39(6):6933-6942.DOI:10.1007/s11033-012-1520-4. [7] Muallem MZ,Marnitz S,Richter R,et al. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation[J]. Anticancer Res, 2014,34(1):401-406. [8] Sakano S,Ogawa S,Yamamoto Y,et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy[J]. Mol Clin Oncol,2013,1(3):403-410.DOI:10.3892/mco.2013.85. [9] 李文华,孙奇,陆妹英.中晚期鼻咽癌中核苷酸切除修复交叉互补基因1表达与铂类药物疗效的相关性研究[J].临床耳鼻咽喉头颈外科杂志,2015,29(2):144-146.DOI:10.13201/j.issn.1001-1781.2015.02.013. [10] Hasegawa K,Kato R,Torii Y,et al. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage Ⅰ to stage Ⅱ uterine cervical adenocarcinoma[J].Int J Gynecol Cancer, 2011,21(8):1479-1485.DOI:10.1097/IGC.0b013e31822265e7. [11] Warnecke-Eberz U, Vallbhmer D,Alakus H,et al. ERCC1 and XRCC1gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer[J].J Gastrointest Surg,2009,13(8):1411-1421.DOI:10.1007/s11605-009-0881-z. [12] Gao Y,Liu D. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers:a systematic review and meta-analysis[J]. Oral Oncol, 2015,51(6):570-577.DOI:10.1016/j.oraloncology.2015.03.009. [13] 刘志刚,陈华云,夏云飞,等.DNA修复基因ERCC1启动子区甲基化与胶质瘤放射敏感性的相关性究[J].中国神经肿瘤杂志,2007,5(3):156-159.
2015, Vol. 24 
